BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 20, 2017--
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that it will host an Investor Symposium in New York City on
December 1, 2017. The event will bring together leading expert
allergists to discuss the emerging treatment landscape in peanut allergy.
Topics at Aimmune’s Investor Symposium will include the practice of
allergy in the community setting, considerations for developing approved
treatment options for food allergy, and treatment expectations in the
peanut allergy community. The Aimmune management team will also review
progress in the Phase 3 clinical development program for AR101, discuss
Phase 2 data for and experience with AR101, and review anticipated
upcoming milestones. AR101 is Aimmune’s investigational oral biologic
desensitization therapy for peanut allergy, which is currently in Phase
3 clinical development. A question and answer session will follow the
Guest Physician Presenters
Ellen R. Sher, MD, is an allergist and immunologist of Allergy
Partners of New Jersey, P.C., Section Chief of Allergy and Immunology at
Monmouth Medical Center, and a Clinical Assistant Professor of Medicine
at Drexel Medical School. Dr. Sher received her medical degree from
Georgetown University and completed her residency at Thomas Jefferson
University Hospital in Philadelphia followed by a fellowship in
pulmonary medicine. She then completed a fellowship in Allergy &
Immunology at the National Jewish Center for Immunology and Respiratory
Medicine. Dr. Sher is a past president of the NJ Allergy, Asthma, &
Immunology Society and current principal investigator of Atlantic
Research Center, where she has participated in over 150 clinical
research studies. Dr. Sher currently serves on several national
committees for The American Academy of Allergy, Asthma & Immunology and
The American College of Allergy, Asthma & Immunology.
Stephen A. Tilles, MD, is Clinical Professor at the University of
Washington, Executive Director of ASTHMA Inc.Clinical Research Center,
and Physician Partner at the Northwest Asthma and Allergy Center. Dr.
Tilles received his medical degree from the University of California at
San Diego. He completed his internship and residency in internal
medicine at the Oregon Health Sciences University, and his allergy and
immunology fellowship at the National Jewish Center for Immunology and
Respiratory Medicine. He was previously an Assistant Professor of
Medicine and Pediatrics and Director of the Allergy and Asthma Clinic at
the Oregon Health Sciences University and has served as principal
investigator for more than 140 clinical research studies. Dr. Tilles is
a past president of the Western Society of Asthma, Allergy and
Immunology and the Oregon Society of Allergy, Asthma, and Immunology. He
is currently Immediate Past-President of the American College of
Allergy, Asthma, and Immunology.
Event and Webcast Details
The Investor Symposium will be held on Friday, December 1, 2017, from
8:00-10:30 a.m. Eastern Time in New York City. Analysts and investors
may register for the event by contacting LifeSci Advisors, LLC, at firstname.lastname@example.org.
A live webcast of the event will be available and may be accessed in the
Investor Relations section of Aimmune’s website at www.aimmune.com
under the Events page. A replay will be available for at least 30 days.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company,
is developing treatments for life-threatening food allergies. Aimmune’s Characterized
Oral Desensitization ImmunoTherapy (CODIT™)
approach is intended to achieve meaningful levels of protection by
desensitizing patients with defined, precise amounts of key allergens.
Aimmune’s first investigational biologic product using CODIT™, AR101 for
the treatment of peanut allergy, has received the FDA’s Breakthrough
Therapy Designation for the desensitization of peanut-allergic patients
4-17 years of age and is currently being evaluated in Phase 3 clinical
trials. For more information, please see www.aimmune.com.
This press release concerns a product that is under clinical
investigation and that has not yet been approved for marketing by the
U.S. Food and Drug Administration (FDA) or the European Medicines Agency
(EMA). It is currently limited to investigational use, and no
representation is made as to its safety or effectiveness for the
purposes for which it is being investigated.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171120005368/en/
Source: Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc.
Laura Hansen, Ph.D.,